Search

Displaying results 3441 - 3450 of 7607 in total
  1. Drug

    Famprofazone

    go.drugbank.com/drugs/DB16702
    Experimental

    [A236369,L34724] Famprofazone is included in the list of prohibited substances specified by the ‘World Anti-Doping Agency’ (WADA).[L34729] … [L34724] It is important to note that the drug is metabolized to [methamphetamine] and [amphetamine] in the body and can lead to positive tests results for illicit drug use.

    Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal
  2. Drug

    Cefotaxime

    go.drugbank.com/drugs/DB00493
    ApprovedInvestigational

    In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).

  3. Drug

    Pimozide

    go.drugbank.com/drugs/DB01100
    Approved

    A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome.

  4. Drug

    Crotamiton

    go.drugbank.com/drugs/DB00265
    Approved

    It is a colorless to slightly yellowish oil, having a faint amine-like odor. It is miscible with alcohol and with methanol.

  5. Drug

    Boldenone

    go.drugbank.com/drugs/DB01541
    ExperimentalIllicitVet approved

    It is not indicated for use in humans in the US and is only available through veterinary clinics.

  6. Drug

    Lesopitron

    go.drugbank.com/drugs/DB04970
    Experimental

    Lesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.

  7. Drug

    Iodamide

    go.drugbank.com/drugs/DB08948
    ApprovedWithdrawn

    Iodamide is a contrast medium molecule that is no longer marketed in the United States.

  8. Drug

    OBE101

    go.drugbank.com/drugs/DB05080
    Experimental

    OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine.

  9. Drug

    BMS-564929

    go.drugbank.com/drugs/DB07286
    Experimental

    So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause. … BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM).

  10. Drug

    Zilebesiran

    go.drugbank.com/drugs/DB18929
    Investigational

    Zilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care